Literature DB >> 3805776

Role of bacterial exopolymers and host factors on adherence and phagocytosis of Staphylococcus aureus in foreign body infection.

E Falcieri, P Vaudaux, E Huggler, D Lew, F Waldvogel.   

Abstract

Using a previously developed guinea pig model of foreign body infection, we examined ultrastructural and functional surface alterations of Staphylococcus aureus strain Wood 46 during the early phase of infection. Exopolymer-free bacteria were prepared and inoculated into subcutaneously implanted tissue cages. After three hours, the bacteria showed abundant capsular and intercellular exopolymers, which were visualized by transmission electron microscopy. Exopolymers were also produced by S. aureus exposed in electron microscopy. Exopolymers were also produced by S. aureus exposed in vitro to fluid from the tissue cage. In contrast, human serum albumin prevented exopolymer production by S. aureus. The influence of exopolymers on the susceptibility of S. aureus to ingestion and phagocytic killing by neutrophils was tested in vitro and found to be negligible. Furthermore, adherence of S. aureus to fibronectin-coated surfaces was unaffected by the presence or absence of exopolymers. Thus, in our experimental model, exopolymers are produced early during the onset of infection, but they have little impact on adherence and phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3805776     DOI: 10.1093/infdis/155.3.524

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Bone and joint infections.

Authors:  T Louie
Journal:  Can J Infect Dis       Date:  1992-03

2.  Effect of plastic catheters on the phagocytic activity of human polymorphonuclear leukocytes.

Authors:  G López-López; A Pascual; E J Perea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

3.  Staphylococcal exopolysaccharides inhibit lymphocyte proliferative responses by activation of monocyte prostaglandin production.

Authors:  R D Stout; K P Ferguson; Y N Li; D W Lambe
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Staphylococcal glycocalyx activates macrophage prostaglandin E2 and interleukin 1 production and modulates tumor necrosis factor alpha and nitric oxide production.

Authors:  R D Stout; Y Li; A R Miller; D W Lambe
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

5.  Noninvasive ventilation for patients near the end of life: what do we know and what do we need to know?

Authors:  William J Ehlenbach; J Randall Curtis
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

6.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

Authors:  A Albus; J M Fournier; C Wolz; A Boutonnier; M Ranke; N Høiby; H Hochkeppel; G Döring
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

Review 7.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

8.  Anti-biofilm activity of an exopolysaccharide from a sponge-associated strain of Bacillus licheniformis.

Authors:  S M Abu Sayem; Emiliano Manzo; Letizia Ciavatta; Annabella Tramice; Angela Cordone; Anna Zanfardino; Maurilio De Felice; Mario Varcamonti
Journal:  Microb Cell Fact       Date:  2011-09-27       Impact factor: 5.328

9.  Antibiofilm activity of an exopolysaccharide from marine bacterium Vibrio sp. QY101.

Authors:  Peng Jiang; Jingbao Li; Feng Han; Gaofei Duan; Xinzhi Lu; Yuchao Gu; Wengong Yu
Journal:  PLoS One       Date:  2011-04-07       Impact factor: 3.240

10.  An association between milk and slime increases biofilm production by bovine Staphylococcus aureus.

Authors:  Mary Hellen Fabres-Klein; Mário Junior Caizer Santos; Raphael Contelli Klein; Guilherme Nunes de Souza; Andrea de Oliveira Barros Ribon
Journal:  BMC Vet Res       Date:  2015-01-16       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.